Business
Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect
Results demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approachesIRVING, Texas, March 31, 2026 /PRNewswire/ -- Caris
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"Results demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approachesIRVING, Texas, March 31, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the finalized Achieve 1 Study results. These results represent a major milestone in Caris' goal to detect cancer earlier, through the future launch of Caris Detect™, its multi-cancer early detection (MCED) test. \n \n \n \n \n \n \n \nCaris Detect leverages Caris' industry-leading molecular profiling data, which has processed more than 1 million cases and generated more than 50 billion molecular markers. This deep molecular foundation enables Caris' AI models to identify, with unprecedented resolution, difficult-to-detect biological signals associated with early-stage cancers. The Achieve 1 Study systematically assessed Caris Detect's diagnostic accuracy across a heterogeneous patient cohort, quantifying its efficacy in identifying multiple cancer types at early stages through peripheral blood sampling. A total of 3,014 subjects were enrolled and evaluable based on high-risk screening, symptomatic presentation, or identification of a mass on imaging, representing a population with elevated cancer prevalence relative to baseline.Achieve 1 results in totality included:InterimBlindedTotalStage I Sensitivity56.8% (n=266)58.4% (n=77)56.8% (n=343)Stage II Sensitivity70.1% (n=137)63.0% (n=54)67.7% (n=191)Stage III Sensitivity77.1% (n=105)84.2% (n=38)79.0% (n=143)Stage IV Sensitivity99.1% (n=109)97.1% (n=36)98.6% (n=145)Asymptomatic Specificity99.1% (n=121)100% (n=20)99.2% (n=141)Benign/High Risk Specificity95.3% (n=1505)98.1% (n=546)96.0% (n=2051)Sensitivity in Stage I and II Cancers 60.3% (n=131)Stage I & II SensitivityCancerInterimBlindedTotalBreast53.0% (n=253) 59.1% (n=44)53.7% (n=297)Prostate78.9% (n=38) 65.0% (n=20)74.1% (n=58)Lung86.7% (n=15) 60.0% (n=15)73.4% (n=30)Uterus73.7% (n=19) 46.1% (n=13)60.6% (n=32)Bowel62.2% (n=45) 60.0% (n=10)61.8% (n=55)Head and Neck100.0% (n=7) 66.7% (n=9)81.3% (n=16)Skin50.0% (n=2) 75.0% (n=4)66.7% (n=6)Pancreas71.4% (n=7) 66.7% (n=3)70.0% (n=10)Other88.2% (n=17)57.1% (n=13)69.7% (n=30)Of note, in the blinded validation set, 36 cancer patients had no staging information, 34 were on treatment or blood was co...